Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)

Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update

American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

Nov 12 – Nov 15, 2021

Alliance Global Partners Biotech & Specialty Pharma Conference

Oct 13, 2021 • 3:00pm EST